UNSPSC 51281913: Pirarubicin

This classification denotes an anthracycline antibiotic, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier D58G680W0G. European Medicines Agency schedules Pirarubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09894MIG. Pirarubicin generally arises in the molecular formula C32H37NO12.

The term PIRARUBICIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 3, no. 3, 1989, list 29.) PIRARUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51281913 Pirarubicin, a Commodity code, shows minimal recent state and local procurement activity directly aligned with the pharmaceutical product itself. The single recent opportunity tagged to this code is a Texas Health and Human Services Commission Request for Information (RFI) issued April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program — a market-intelligence exercise focused on procurement strategy and direct contracting models rather than the purchase of pirarubicin or any specific pharmaceutical product. The RFI solicits vendor experience with direct contracts between state agencies and manufacturers outside traditional pharmacy benefit managers, group purchasing organizations, and wholesalers, with emphasis on negotiated net pricing and outcomes-based agreements.

The code shows negligible activity across state and local jurisdictions. The Texas HHS Commission remains the only identified issuing body with a recent posting, and the RFI itself is exploratory rather than a binding competitive procurement. No response date, award value, or geographic spread beyond Texas is evident in current records. The preliminary nature of the Texas solicitation — designed to inform future formal Request for Proposal development rather than commit to specific contract terms — means the code does not currently reflect active purchasing demand for pirarubicin or related oncology pharmaceuticals at the state and local level. Business development professionals should monitor Texas HHS Commission notices for downstream RFP activity following this information-gathering phase, but the code presents no actionable near-term opportunity.